- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00827632
Obesity, Oral Contraception, and Ovarian Suppression (20/30)
Oral Contraception and Ovarian Suppression in Women With Different Weights
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
New York
-
New York, New York, Forenede Stater, 10032
- Columbia University Medical Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Aged 18-35
- Body Mass Index (BMI) 19-24.9 or 30-39.9 kg/m^2
- Willing to take birth control pills for 3-4 months
- Recent spontaneous pregnancy or cyclic menses
Exclusion Criteria:
- Contraindications to hormonal contraceptives
- Oophorectomy/Polycystic ovary syndrome (PCOS)
- Taken oral contraceptives to regulate menses recently
- Weight reduction surgery
- Used Depo-Provera within the last 12 months
- Pregnant or currently breastfeeding
- Desiring pregnancy within the next 4 months
- Unable to make study visit commitment
- Previous participation in this study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Aktiv komparator: Normal Weight group
Participants with a BMI of 19-24.9
kg/m^2
|
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
Andre navne:
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
Andre navne:
|
Aktiv komparator: Obese group
Participants with a BMI of 30-39.9
kg/m^2
|
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet.
Andre navne:
Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use. Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Risk of Oral Contraceptive (OC) Failure Due to Less Contraceptive-mediated Ovarian Suppression.
Tidsramme: Up to 8 biweekly visits from start of OCP therapy
|
Perpendicular diameter, ethinyl estradiol, and progesterone values were used to create Hoogland Scores. Hoogland Scores were used to assess ovarian suppression during OC use. The Hoogland Score comprises 6 grades (Because of small numbers, grades 5 and 6 were combined):
Each participant received a score from 1-6 to indicate the level of ovarian suppression; total number of participants were tallied for each Hoogland score. |
Up to 8 biweekly visits from start of OCP therapy
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Lipid or Carbohydrate Metabolism in Obese Versus Normal Weight Oral Contraceptive (OC) Users at Baseline and Exit Visit (12-16 Weeks OC Exposure).
Tidsramme: Screening (baseline) and follow-up 1 (exit)
|
Screening (baseline) and follow-up 1 (exit)
|
Pharmacokinetics of 15 Obese Weight and 15 Normal Weight Women on Combined Oral Contraceptives.
Tidsramme: 24 hours during week 3 of follow-up cycle
|
24 hours during week 3 of follow-up cycle
|
Samarbejdspartnere og efterforskere
Sponsor
Publikationer og nyttige links
Generelle publikationer
- Mayeda ER, Torgal AH, Westhoff CL. Weight and body composition changes during oral contraceptive use in obese and normal weight women. J Womens Health (Larchmt). 2014 Jan;23(1):38-43. doi: 10.1089/jwh.2012.4241. Epub 2013 Oct 24.
- Westhoff CL, Torgal AH, Mayeda ER, Stanczyk FZ, Lerner JP, Benn EKT, Paik M. Ovarian suppression in normal-weight and obese women during oral contraceptive use: a randomized controlled trial. Obstet Gynecol. 2010 Aug;116(2 Pt 1):275-283. doi: 10.1097/AOG.0b013e3181e79440.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- AAAB4823
- R01HD045786 (U.S. NIH-bevilling/kontrakt)
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Ovarian Suppression
-
Second Affiliated Hospital of Xi'an Jiaotong UniversityChinese Medical AssociationUkendtHæmodynamisk ustabilitet | Adrenal suppression
-
Sheffield Children's NHS Foundation TrustRekrutteringAdrenal suppressionDet Forenede Kongerige
-
Mayne Pharma International Pty LtdAfsluttetPlaque PsoriasisForenede Stater, Polen, Ukraine, Georgien
-
Taro Pharmaceuticals USAAfsluttetPlaque PsoriasisForenede Stater
-
Primus PharmaceuticalsProsoft ClinicalAfsluttet
-
Taro Pharmaceuticals USAAfsluttet
-
The Nazareth Hospital, IsraelAfsluttetAdrenal suppression
-
Taro Pharmaceuticals USAAfsluttetPlaque PsoriasisForenede Stater
-
Cassiopea SpAAfsluttetAcne VulgarisForenede Stater, Polen
-
Taro Pharmaceuticals USAAfsluttetPlaque PsoriasisForenede Stater
Kliniske forsøg med Low dose formulation
-
Tongji HospitalRekrutteringRemimazolam | Vågen endotracheal intubationKina
-
Contrad Swiss SAAfsluttetKnæ slidgigt | Knæskader | Smerter, Akut | Knæ arthritis | Smerte, kronisk | Knæsmerter HævelseItalien
-
Contrad Swiss SAAfsluttetLangt hoved af bicepsrupturItalien
-
Riphah International UniversityAfsluttetHamstring StramhedPakistan
-
Ohio State UniversityAfsluttetDiabetes mellitus, type 2 | Blodglukose, høj | Patientudskrivning | Blodglukose, lavForenede Stater
-
Contrad Swiss SAAfsluttet
-
University Hospital, Clermont-FerrandAfsluttet
-
University of MichiganNational Institute on Drug Abuse (NIDA); Brown University; Pennington Biomedical... og andre samarbejdspartnereRekruttering
-
University Hospital, Basel, SwitzerlandRekrutteringFedme | GlucoseintoleranceSchweiz
-
Medical University of WarsawNutricia FoundationUkendt